Sana Biotechnology Annual Global Healthcare Conference Key Takeaways

Goldman Sachs recaps key investor conference takeaways for Sana Biotechnology, highlighting 2026 clinical milestones for its SG293 and SC451 programs. The company maintains a cash runway through mid-2027 to achieve key proof-of-concept readouts.

Key Takeaways

• 1.Phase 1 study initiation for SG293 in non-Hodgkin lymphoma is expected in 2026, with potential for autoimmune expansion.
• 2.Lead iPSC-derived SC451 therapy for T1D is in IND-enabling studies with a clinic transition planned for 2026.
• 3.Management reports a pro-forma cash position of $195mn, providing runway into mid-2027.

Table of Contents

• Key Takeaways
• Valuation/Risks
• Disclosure Appendix

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial